VentriPoint Diagnostics

VPT.V

Medical - Devices · Healthcare

Price

C$0.10

-0.01 (-5.00%)

Market Cap

C$17.8M

Exchange

Toronto Stock Exchange Ventures

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+21.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 136.1M (2021) → 165.4M (2025)

Winston Score History

The full picture

VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+81.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

C$372,910/ year

↓ Declining (-62% vs prior year)

207.3% of revenue

11.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Cash Runway

~0 months

C$55,389 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

VentriPoint Diagnostics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-258.6%

Thin — -258.6% gross margin

Profit after running costs

Operating Margin

-17160.9%

Losing money on operations — -17160.9%

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+89.1%

Fast-growing sales (+89.1% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-864.2%

Burning cash (-864.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial